Engflag

Mesacol-OD

Quick links to important sections

Mesacol-OD

Mesacol-OD_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mesacol-OD

Quick Facts

Property Description
Active ingredient Mesalamine (or Mesalazine)
Form Oral sustained-release tablet
Pharmacological class Aminosalicylate Anti-inflammatory Agent
General use Management of chronic intestinal inflammation
Origin Synthetic derivative of 5-Aminosalicylic acid (5-ASA)

What is Mesacol-OD and its Pharmacological Class?

Mesacol-OD is a specialized prescription medicine whose sole active substance is Mesalamine, chemically synonymous with Mesalazine. This compound is classified pharmacologically as an Aminosalicylate anti-inflammatory agent, a designation recognized by major health organizations. Mesalamine is a synthetic derivative of 5-Aminosalicylic acid (5-ASA), and it functions primarily as a local anti-inflammatory agent within the digestive system. Its role is strictly defined by its composition and class, establishing it as a core medication type clinically recognized for its anti-inflammatory efficacy in the lower bowel.

Understanding the Oral Sustained-Release Tablet

The preparation is formulated as an oral sustained-release tablet for administration, a design indicated by the "OD" designation, which refers to its intended once-daily dosing profile. This is a single active ingredient product, distinguishing it from older combination therapies such as Sulfasalazine. The physical tablet structure uses specialized pharmaceutical excipients to create a unique delivery system. This proprietary release technology is a key differentiating feature, allowing for a consistent, targeted supply of the active substance. The precise coating ensures the Mesalamine is protected during transit, allowing its continuous release to occur specifically in the colon and rectum.

What is the General Benefit of Mesalamine?

The general benefit derived from Mesacol-OD is based on its localized anti-inflammatory function. The medicine’s core purpose is to reduce the production of specific inflammatory mediators within the lining of the bowel. Its mechanism relies on its ability to inhibit key inflammatory pathways, which helps suppress the production of inflammation-causing substances in the gut. By delivering a targeted supply of the active Mesalamine directly to the site of inflammation, the drug helps to control and soothe the chronic irritation and swelling that characterize inflammatory processes in the large intestine. A typical use scenario involves stabilizing the intestinal environment to manage inflammation long-term.

Regulatory References

  1. WHO Essential Medicines List for Mesalazine
  2. Mesalamine (USAN) - StatPearls - NIH

What side effects are possible with Mesacol-OD?

Mesalamine: Documented Side Effects and Safety Characteristics

Adverse reactions associated with mesalamine, the active substance in Mesacol-OD, are categorized in official regulatory documents based on frequency and the affected System-Organ Class (SOC). The safety profile is structured to communicate both common, expected reactions and specific, serious safety constraints.

Reactions commonly reported in clinical trials include headache, nausea, abdominal pain, and nasopharyngitis. Less frequent effects are often classified under nervous system (e.g., dizziness) and skin disorders (e.g., rash, pruritus).

Serious adverse reactions highlighted in regulatory warnings include Renal Impairment, such as acute or chronic interstitial nephritis, and severe Hypersensitivity Reactions that may affect internal organs, including myocarditis and hepatitis. Another clinically significant event documented is Mesalamine-Induced Acute Intolerance Syndrome, which involves acute symptoms like cramping and bloody diarrhea, often manifesting shortly after therapy initiation.

Population-specific safety considerations are stated in official labels. Older adults may have a higher incidence of specific blood disorders and decreased organ function. Caution is advised for individuals with pre-existing hepatic or renal impairment due to the drug’s metabolic pathway and potential for nephrotoxicity. The medication is absolutely contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates. Regulatory documents also caution that concurrent use with certain other agents, such as nephrotoxic drugs, may increase the risk of specific adverse effects, such as renal toxicity.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation notes that instances of acute human overdose with mesalamine are rare, providing limited specific data on clinical signs. Potential acute manifestations associated with overexposure, often referencing aminosalicylate toxicity, may include nausea, vomiting, abdominal pain, headache, dizziness, confusion, fast or shallow breathing, and seizures.

While human data on overdosage generally do not indicate renal or hepatic toxicity, preclinical studies included in prescribing information identify the kidney as the major target organ for toxicity at high doses. This established risk profile mandates specific actions.

It is officially required to seek immediate medical attention for any suspected overdosage. No specific antidote is available, therefore treatment is strictly symptomatic and supportive. Due to the potential for severe effects, the official management procedure includes the necessity for close monitoring of renal function and correcting fluid and electrolyte imbalances. Emergency services must be contacted immediately if severe symptoms, such as collapse, seizure, or respiratory distress, are observed.

Therapeutic Uses of Mesacol-OD

Main Uses and Benefits of Mesacol-OD

Mesacol-OD is an anti-inflammatory medication primarily used to manage specific chronic inflammatory bowel diseases (IBD). It contains the active ingredient mesalamine (also known as 5-aminosalicylic acid), which works locally in the digestive tract to reduce inflammation.

Ulcerative Colitis

The primary application of Mesacol-OD is in the treatment of ulcerative colitis, a condition characterized by inflammation and sores (ulcers) in the lining of the colon and rectum. The medication is used for two main purposes:

  • Induction of Remission: During an active flare-up, the medication helps to reduce the swelling and redness of the intestinal lining, aiming to stop symptoms such as abdominal pain and frequent bowel movements.
  • Maintenance of Remission: Once the inflammation is under control, long-term use of the medication helps prevent the symptoms from returning, keeping the disease in a quiescent or stable state.

Mechanism of Action

Mesacol-OD is designed as an "extended-release" or "once-daily" (OD) formulation. This allows the active ingredient to be released gradually as it passes through the intestinal tract. Unlike systemic anti-inflammatories that circulate throughout the entire body, this medication acts topically on the inner lining of the gut.

By inhibiting the production of certain chemicals that cause inflammation, the medication helps the intestinal tissue heal. This localized action is intended to manage the disease at the source of the inflammation while minimizing impact on other organ systems.

Therapeutic Benefits

For individuals living with chronic intestinal inflammation, the consistent use of this medication can lead to several clinical benefits:

  • Reduction in the frequency of diarrhea and rectal bleeding.
  • Decrease in general abdominal discomfort associated with inflammation.
  • Improved quality of life by extending the periods between active disease flares.
  • Support in the long-term mucosal healing of the bowel wall.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mesacol-OD?

The population eligibility for Mesacol-OD (Mesalamine) is strictly defined by regulatory documents, distinguishing between approved, conditional, and contraindicated groups.

Contraindicated Populations

Use of Mesacol-OD is strictly prohibited in patients with the following conditions as specified in regulatory labeling:

  • Known or suspected hypersensitivity to salicylates (like aspirin), aminosalicylates (Mesalamine/5-ASA), or any of the product's excipients.
  • Severe hepatic impairment or severe renal impairment.

Age-Related Eligibility

Age Group Regulatory Eligibility Status
Adults Established for induction and maintenance of remission in mildly to moderately active ulcerative colitis.
Pediatric Established for children generally aged 5 years and older or weighing at least 24 kg (varies by specific formulation). Safety is not established below these limits.
Older Adults Use requires caution and monitoring of renal/hepatic function due to age-related risk.

Conditional Use Restrictions

Some populations require conditional use with mandatory monitoring or risk evaluation:

  • Renal or Hepatic Impairment: Patients with existing non-severe impairment must have organ function evaluated before and periodically during treatment. Discontinuation is required if function deteriorates.
  • Pregnancy and Lactation: Use is conditional and recommended only if clearly needed, as the substance is excreted into breast milk, requiring the infant to be monitored.
  • Gastrointestinal Obstruction: Use is not recommended in patients with pyloric or other upper GI tract obstruction due to the specific oral delivery mechanism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Mesalamine (Mesacol-OD) defines several clinically significant drug-drug and substance interactions. These interactions generally fall into categories of altered drug exposure, additive toxicity, and interference with the formulation’s specialized release mechanism.

Official Interaction Statements

Classification Interacting Agents Regulatory Requirement/Outcome
Exposure Modification Azathioprine, 6-Mercaptopurine, Thioguanine Increased risk of myelosuppression (blood disorders) due to Mesalamine's reported inhibition of the TPMT enzyme. Mandated monitoring of blood cell counts.
Pharmacodynamic Risk Nephrotoxic Agents (including NSAIDs) Increased risk of nephrotoxicity (renal adverse reactions) due to an officially stated additive effect. Requires monitoring of renal function.
Delivery Interference Lactulose or similar low pH agents May prevent the required release of Mesalamine from its delayed-release formulation in the colon.
GI/Systemic Coumarin-type Anticoagulants (e.g., Warfarin) Potential alteration of the anticoagulant effect (increase or decrease). Requires close monitoring of prothrombin time/INR.

Administration and Laboratory Interference

Co-administration with Antacids can also be associated with a decrease in the systemic absorption of the active substance. Furthermore, Mesalamine is documented to interfere analytically with specific laboratory tests: the drug's metabolite may cause spuriously elevated test results when measuring urinary normetanephrine via liquid chromatography with electrochemical detection.

The regulatory profile also includes a population-specific interaction note, emphasizing that the potential for nephrotoxicity must be carefully evaluated in patients with known renal impairment or those taking concomitant nephrotoxic drugs.

Mechanism of Action

How Mesacol-OD Works

Mesacol-OD (Mesalazine/5-ASA) is a drug whose mechanism of action is primarily localized to the colonic mucosa. The active component, 5-aminosalicylic acid (5-ASA), modulates processes characteristic of inflammation through multiple pathways.

5-ASA interferes with the synthesis of pro-inflammatory lipid mediators. It is thought to influence the activity of enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which contributes to the inhibition of inflammatory mediator production, including prostaglandins and leukotrienes.

Intracellularly, 5-ASA modulates the function of transcription factors. It can inhibit Nuclear Factor kappa B (NF-kB), a key regulator of pro-inflammatory gene expression, and engage PPAR-gamma, a nuclear receptor associated with anti-inflammatory signaling. This alters gene expression patterns in immune cells and modifies the overall signaling dynamics of the immune response within the intestinal lining.

Additionally, Mesalazine engages mechanisms that act as a direct scavenger of reactive oxygen species (ROS), thereby influencing the cellular environment impacted by oxidative stress.

Dosage and Administration Information

How to Use Mesacol-OD: Administration Guidelines

Mesacol-OD is a medication whose administration guidelines are based on its sustained-release formulation. The primary instruction specifies oral administration only. Its usage pattern is structured around a once-daily dosing frequency for both the initial treatment period and long-term maintenance.

Administration Scope

Feature Guideline
Route of Administration Oral administration for the delayed-release tablet.
Dosing Schedule Induction of Remission: 2.4 g to 4.8 g total daily dose. Maintenance of Remission: 2.4 g total daily dose.
Timing in Relation to Meals Must be administered with food (a meal).
Age-Group Rules Dosing for pediatric patients weighing 24 kg or more is weight-based.
Special Procedural Conditions The tablets must be swallowed whole and cannot be cut, crushed, or broken to preserve the intended release profile.

Procedural Structure and Course Duration

The treatment protocol involves a two-phase duration. The initial course for induction of remission is specified to be up to 8 weeks. Following this initial period, the lower 2.4 g total daily dose is continued for the long-term maintenance of remission. The requirement to take the tablet once daily alongside a meal establishes a consistent administration pattern for the drug's release within the digestive system. Furthermore, renal function is evaluated before beginning therapy and monitored periodically during the treatment course.

Recent Clinical Evidence

Research evidence / Overview of studies for Mesacol-OD

Research for Ulcerative Colitis (UC) – Inducing Periods of Stability

Research has examined Mesacol-OD in conditions characterized by fluctuating or episodic manifestations. These studies were primarily applied in research contexts involving fluctuating or unstable symptoms, where research examined short-term symptom changes. The evidence focused on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

When Mesacol-OD was studied for initiating periods of stability, research describes patterns related to outcomes reflecting daily functioning or activity level. Studies report how symptoms evolved in the observed populations, and studies monitored patterns related to periods of stability. The findings help contextualize how patients reported their experience during these studies. Findings were mixed on how symptom patterns evolved.

Research for Ulcerative Colitis (UC) – Maintaining Periods of Stability

Studies have also explored Mesacol-OD for its use in long-term management of conditions presenting with cycles of stability and flare-ups. This research was used in observational settings evaluating daily-life functioning. Research highlights changes measured during the study period; studies monitored patterns related to sustaining these periods of low symptom activity. This evidence contributes to the broader research landscape related to outcomes monitoring physiological strain or stress.

Long-term effects are not fully established, as follow-up durations were limited in some of the maintenance studies. Data are still emerging for specific outcomes related to systemic or functional imbalance over extended time. Comparative evidence against other interventions is lacking for maintenance in conditions where symptoms may vary in intensity.

Evidence in Specific Patient Groups and Remaining Uncertainties

Research explored Mesacol-OD for Crohn's disease, a condition marked by functional limitations. Findings from studies were mixed, and the evidence base appears limited relative to the research available for Ulcerative Colitis. The evidence concerning special populations, such as pediatric patients, was observed in some studies but remains limited. For pregnant and lactating patients, there is limited information, and certainty remains low regarding long-term outcomes. Overall, results apply only to the populations studied, and evidence quality varies across studies.

How should Mesacol-OD be stored and disposed of?

How to Store and Dispose of Mesacol-OD?

The official storage and disposal requirements for Mesacol-OD (Mesalamine sustained-release tablets) ensure the product's quality and public safety.

Storage Conditions

  • Temperature: Store at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F), protecting the medication from moisture. Do not store outside of the permitted excursion range, and do not freeze the product.
  • Container: The tablets must remain in the original container, which should be kept tightly closed to maintain the stability of the sustained-release formulation.
  • Safety: Always store the medication out of the sight and reach of children.

Disposal Instructions

Disposal must follow regulatory guidance. Unused or expired medication should be disposed of through a drug take-back program or by mixing it with an unappealing substance, sealing it, and placing it in the household trash. It is required to scratch out all personal information on the prescription label before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mesacol-OD found in:

A-Z Index: